Pioneering the Next Generation of Targeted Medicine
Neologics Bioscience was founded on a singular conviction: that the future of medicine lies in precision — not approximation. We engineer therapeutic molecules that find their targets with sub-nanomolar accuracy, sparing healthy tissue and transforming outcomes for patients who have run out of options.
Redefining What's Possible in Drug Discovery
"To engineer precision therapeutics that eliminate disease at the molecular level — delivering transformative outcomes for patients, and a new paradigm for medicine."
Scientific Rigor
Every claim we make is backed by reproducible data. We hold our science to the highest standard because patients depend on it.
Relentless Innovation
We challenge established approaches and pursue unconventional solutions when the science demands it.
Patient Centricity
Every program we advance is anchored to a real unmet need. The patient is never an abstraction.
Transparent Partnership
We build trust with investors, collaborators, and regulators through open, evidence-based communication.
Built From First Principles
Neologics Bioscience emerged from a decade of foundational research into receptor biology and intracellular delivery mechanisms. Our founders recognized that existing targeted therapy platforms were constrained by fundamental limitations in ligand design — and set out to solve the problem from scratch. The result is the Neologicals platform: a proprietary framework for engineering sub-nanomolar ligands that bind with extraordinary selectivity and deliver therapeutic payloads directly to diseased cells.
Company founded; core receptor-targeting IP established
Series A financing; Neologicals platform validated in vitro
Preclinical proof-of-concept: 87% tumor reduction in EGFR+ xenograft models
IND filing for Neologicals-001; Series B financing closed
Phase I/II trial initiated for Neologicals-001 in advanced solid tumors
Four active programs; Phase I/II interim data expected H2 2026
The Team Behind the Science
Our leadership team brings together deep expertise in drug discovery, clinical development, and biotech company building — united by a shared commitment to advancing the Neologicals platform.
Dr. Elena Vasquez
Former VP of Drug Discovery at a top-10 pharma. 20+ years in oncology therapeutics. Led three INDs and two Phase II programs to successful completion.
Dr. Marcus Chen
Pioneered receptor-targeted delivery systems at Stanford. Author of 40+ peer-reviewed publications. Architect of the Neologicals platform technology.
Dr. Sarah Okafor
Board-certified oncologist with 15 years of clinical trial experience. Previously led Phase I/II programs at two leading oncology-focused biotechs.
James Whitfield
Veteran biotech CFO with experience across four successful IPOs and multiple strategic partnerships. Deep expertise in life sciences capital markets.
Dr. Priya Nair
Leads the bridge from preclinical discovery to clinical development. Expert in biomarker strategy and patient selection for precision oncology trials.
Dr. Thomas Reeves
20 years in process chemistry and CMC development. Oversees scale-up of Neologicals conjugates from milligram to kilogram scale.
Guided by World-Class Expertise
Prof. David Hartmann
Receptor pharmacology and targeted oncology
Dr. Yuki Tanaka
Clinical trial design and solid tumor immunology
Prof. Amara Diallo
Computational drug design and molecular modeling
Dr. Robert Stein
Regulatory strategy and accelerated approval pathways
Join Us in Rewriting the Rules of Medicine
We are actively seeking strategic partners, institutional investors, and world-class talent who share our conviction that precision medicine is the future of oncology.